Momenta Pharmaceuticals (MNTA) Downgraded by BidaskClub to Hold

Momenta Pharmaceuticals (NASDAQ:MNTA) was downgraded by equities researchers at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.

A number of other equities analysts have also weighed in on the stock. Zacks Investment Research raised shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. Cowen set a $15.00 target price on shares of Momenta Pharmaceuticals and gave the stock a “hold” rating in a research note on Wednesday, November 1st. Robert W. Baird lowered shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating and reduced their target price for the stock from $22.00 to $15.00 in a research note on Friday, October 6th. ValuEngine lowered shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, October 6th. Finally, JPMorgan Chase & Co. reaffirmed a “hold” rating and issued a $14.00 target price on shares of Momenta Pharmaceuticals in a research note on Thursday, October 5th. Two research analysts have rated the stock with a sell rating and ten have given a hold rating to the company. The company has a consensus rating of “Hold” and an average price target of $15.00.

Shares of Momenta Pharmaceuticals (NASDAQ MNTA) opened at $15.50 on Thursday. Momenta Pharmaceuticals has a 1 year low of $11.85 and a 1 year high of $19.90. The company has a market cap of $1,180.00, a price-to-earnings ratio of -19.38 and a beta of 1.66.

Momenta Pharmaceuticals (NASDAQ:MNTA) last released its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.44) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.47) by $0.03. Momenta Pharmaceuticals had a negative net margin of 55.61% and a negative return on equity of 16.20%. The business had revenue of $24.09 million during the quarter, compared to analysts’ expectations of $29.58 million. During the same quarter in the prior year, the company earned ($0.26) EPS. The firm’s quarterly revenue was down 17.3% on a year-over-year basis. equities analysts forecast that Momenta Pharmaceuticals will post -1.16 earnings per share for the current year.

In other news, Director Elizabeth Stoner sold 5,500 shares of the stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $13.10, for a total transaction of $72,050.00. Following the completion of the transaction, the director now directly owns 13,240 shares in the company, valued at approximately $173,444. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Craig A. Wheeler sold 35,666 shares of the stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $14.11, for a total transaction of $503,247.26. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 49,505 shares of company stock valued at $685,923. Company insiders own 4.40% of the company’s stock.

Several institutional investors have recently bought and sold shares of MNTA. Schwab Charles Investment Management Inc. boosted its stake in shares of Momenta Pharmaceuticals by 22.1% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 358,055 shares of the biotechnology company’s stock worth $6,052,000 after buying an additional 64,817 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Momenta Pharmaceuticals by 6.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 841,036 shares of the biotechnology company’s stock worth $14,213,000 after buying an additional 47,301 shares during the last quarter. Legal & General Group Plc boosted its stake in shares of Momenta Pharmaceuticals by 12.8% during the 2nd quarter. Legal & General Group Plc now owns 126,887 shares of the biotechnology company’s stock worth $2,145,000 after buying an additional 14,424 shares during the last quarter. Prudential Financial Inc. boosted its stake in shares of Momenta Pharmaceuticals by 8.1% during the 2nd quarter. Prudential Financial Inc. now owns 118,068 shares of the biotechnology company’s stock worth $1,996,000 after buying an additional 8,876 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of Momenta Pharmaceuticals by 4.9% during the 2nd quarter. Principal Financial Group Inc. now owns 541,686 shares of the biotechnology company’s stock worth $9,154,000 after buying an additional 25,144 shares during the last quarter. Institutional investors own 93.40% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/18/momenta-pharmaceuticals-mnta-downgraded-by-bidaskclub-to-hold.html.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Analyst Recommendations for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply